Literature DB >> 7295516

Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.

J L Moore, I C Paterson, H Newman, S Venables.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7295516      PMCID： PMC2010798          DOI： 10.1038/bjc.1981.232

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  13 in total

1.  Peripheral neuropathy related to misonidazole: incidence and pathology.

Authors:  R C Urtasun; J D Chapman; M L Feldstein; R P Band; H R Rabin; A F Wilson; B Marynowski; E Starreveld; T Shnitka
Journal:  Br J Cancer Suppl       Date:  1978-06

2.  Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer.

Authors:  N J McNally; J Denekamp; P Sheldon; I R Flockhart; F A Stewart
Journal:  Radiat Res       Date:  1978-03       Impact factor: 2.841

3.  The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.

Authors:  T H Wasserman; T L Phillips; G Van Raalte; R Urtasun; J Partington; D Koziol; J G Schwade; D Gangji; J M Strong
Journal:  Br J Radiol       Date:  1980-02       Impact factor: 3.039

4.  Pilot study of radiotherapy with misonidazole in head and neck cancer.

Authors:  I C Paterson; P J Dawes; J M Henk; J L Moore
Journal:  Clin Radiol       Date:  1981-03       Impact factor: 2.350

5.  Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.

Authors:  P Workman; C J Little; T R Marten; A D Dale; R J Ruane; I R Flockhart; N M Bleehen
Journal:  J Chromatogr       Date:  1978-05-01

6.  Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.

Authors:  T H Wasserman; T L Phillips; R J Johnson; C J Gomer; G A Lawrence; W Sadee; R A Marques; V A Levin; G VanRaalte
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-06       Impact factor: 7.038

7.  Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.

Authors:  P Workman; N M Bleehen; C R Wiltshire
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

8.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

9.  Distribution of misonidazole in human tumours and normal tissues.

Authors:  D V Ash; M R Smith; R D Bugden
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

10.  Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.

Authors:  P Workman
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640
View more
  3 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Misonidazole neurotoxicity in rats: Part II. Effect of pre- and intermittent treatment with pentobarbital on misonidazole neurotoxicity in the rat.

Authors:  M S Edwards; D G Gordon; A Salamy; V A Levin; T L Phillips
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

3.  The role of dexamethasone in the modification of misonidazole pharmacokinetics.

Authors:  D H Jones; N M Bleehen; P Workman; M I Walton
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.